Catalyst
Slingshot members are tracking this event:
Anti-Cancer Agent “Xeloda”, Obtained Approval for Additional Indication of “Adjuvant Chemotherapy for Rectal Cancer”
- Source Link:
- http://www.roche.com/inv-update-2016-08-26.pdf
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
RHHBY |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 26, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Xeloda, Rectal Cancer, Adjuvant Chemotherapy